Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215136 · ClinicalTrials.gov registry record · Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
A Phase 2 study, sponsored by Matthew Galsky.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01215136 is a Phase 2 study that was terminated before completion, run by Matthew Galsky. The registered enrollment target is 36 participants.
The verdict
NCT01215136, a Phase 2 study, was terminated before completion, sponsored by Matthew Galsky.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Interventions
- DRUG Paclitaxel
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-12 |
| Est. Completion | 2018-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215136
The ClinicalTrials.gov registry entry for NCT01215136 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01215136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215136 about?
NCT01215136 is a clinical study titled "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma". The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
What is the current status of trial NCT01215136?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2010-12. Estimated completion is 2018-04-24.
What interventions are being tested in trial NCT01215136?
The interventions under investigation include: Paclitaxel (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT01215136?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.